Degarelix: all 85 studies that test it

Page 1 of 1. Open to participants first (5), then studies with results posted, then the rest; newest registration first within each.

• Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CTRecruitingNCT07455903Phase 2
• Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular TracersRecruitingNCT06282588Phase 2/3
• NeoAdjuvant Theranostic Lutetium Study: The Nautilus TrialRecruitingNCT06066437Phase 1/2
• ETHAN - ET for Male BCRecruitingNCT05501704Phase 2
• Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate CancerNot yet recruitingNCT04176081Phase 2
• Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring HospitalizationCompletedNCT04397718Phase 2Results posted
• Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate CancerActive, not recruitingNCT03361735Phase 2Results posted
• Phase II Study of Docetaxel Before Degarelix in Patients With Newly Diagnosed Metastatic Prostate Cancer.CompletedNCT03069937Phase 2Results posted
• Trial of ADT and SBRT Versus SBRT for Intermediate Prostate CancerTerminatedNCT03056638Phase 3Results posted
• A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomyCompletedNCT02849990Phase 2Results posted
• A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular DiseaseTerminatedNCT02663908Phase 3Results posted
• Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate CancerTerminatedNCT02560051Phase 2Results posted
• Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate CancerTerminatedNCT02494713Phase 2Results posted
• Dysregulation of FSH in Obesity: Functional and Statistical AnalysisCompletedNCT02478775Not applicableResults posted
• TRial on the Endocrine Activity of Neoadjuvant DegarelixCompletedNCT02005887Phase 2Results posted
• 3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical ProstatectomyCompletedNCT01751451Phase 2Results posted
• Degarelix Acetate Before and During Radiation Therapy in Treating Patients With Prostate CancerCompletedNCT01731912Not applicableResults posted
• Androgen Deprivation Therapy Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate CancerCompletedNCT01542021Not applicableResults posted
• A Degarelix Trial in Patients With Prostate CancerTerminatedNCT01242748Phase 3Results posted
• A Study of Degarelix in Taiwanese Patients With Prostate CancerCompletedNCT01220869Phase 3Results posted
• Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Korean PatientsCompletedNCT01215513Phase 3Results posted
• Efficacy and Safety of Degarelix One Month Dosing Regimen in Korean Patients With Prostate CancerCompletedNCT01071915Phase 3Results posted
• A Long Term Safety Study of Degarelix in Patients With Prostate CancerCompletedNCT00967018Phase 3Results posted
• A Trial of Degarelix in Men With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)CompletedNCT00947882Phase 2Results posted
• A Trial of Degarelix in Patients With Prostate CancerCompletedNCT00946920Phase 3Results posted
• A Study of Degarelix in Patients With Prostate CancerCompletedNCT00928434Phase 3Results posted
• Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer PatientsCompletedNCT00884273Phase 3Results posted
• Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate CancerCompletedNCT00833248Phase 3Results posted
• Symptomatic Study Investigating Degarelix in Patients Suffering From Prostate CancerTerminatedNCT00831233Phase 3Results posted
• The Efficacy and Safety of FE 200486 in Treatment of Patients Suffering From Prostate CancerCompletedNCT00819247Phase 2Results posted
• Dose Finding Trial With a New Treatment (Degarelix) for Prostate CancerCompletedNCT00819156Phase 2Results posted
• Investigation of a New Trial Drug (FE200486) in Prostate Cancer PatientsCompletedNCT00818623Phase 2Results posted
• Intermittent Treatment With Degarelix of Patients Suffering From Prostate CancerCompletedNCT00801242Phase 3Results posted
• Degarelix as Second-Line Hormonal Treatment After Prostate-specific Antigen (PSA)-Failure in GnRH Agonist Treated Patients With Prostate CancerCompletedNCT00738673Phase 2Results posted
• Explorative Study of Degarelix for Treatment of Benign Prostatic Hyperplasia.CompletedNCT00527488Phase 2Results posted
• Investigating Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Ablation TherapyCompletedNCT00468286Phase 2Results posted
• A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation TherapyCompletedNCT00451958Phase 3Results posted
• The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate CancerCompletedNCT00295750Phase 3Results posted
• Extension Study Investigating the Long-Term Safety of Degarelix Three-Month Depots in Patients With Prostate CancerCompletedNCT00268892Phase 2/3Results posted
• Study Investigating the Long-Term Safety and Tolerability of Repeated Doses of Degarelix in Prostate Cancer PatientsTerminatedNCT00245466Phase 2Results posted
• An Extension Study Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Depots in Prostate CancerCompletedNCT00215683Phase 2/3Results posted
• Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer PatientsTerminatedNCT00215657Phase 2Results posted
• Study Investigating the Pharmacokinetics, Pharmacodynamics and Safety of FE200486CompletedNCT00117949Phase 2Results posted
• Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer PatientsTerminatedNCT00117312Phase 2Results posted
• Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate CancerCompletedNCT00117286Phase 2/3Results posted
• A Parallel Group Comparison of the Efficacy and Safety of Degarelix at Two Different Dosing Regimens in Patients With Prostate CancerCompletedNCT00116779Phase 2Results posted
• A Comparative Study of Degarelix Three-month Depot in Three Different Dosing Regimens in Patients With Prostate CancerCompletedNCT00116753Phase 2Results posted
• A Study of BMS986365 in Combination With Degarelix in People With Prostate CancerActive, not recruitingNCT07335796Phase 2
• A Study of Copanlisib in Combination with Degarelix in People with Prostate CancerWithdrawnNCT06218667Phase 1/2
• Neoadjuvant ADT With TULSA in the Treatment of Intermediate Risk Prostate CancerActive, not recruitingNCT05917860Phase 1
• Targeting Androgen Signaling in Urothelial Cell Carcinoma - NeoadjuvantTerminatedNCT05839119Phase 1
• Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate CancerStatus unknownNCT05212857Phase 2
• Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance TrialActive, not recruitingNCT05050084Phase 3
• Interest of PET-PSMA Imaging Potentialised by Androgen Blockade in Localized Prostatic AdenocarcinomaCompletedNCT04391556Phase 2
• Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate CancerCompletedNCT04301414Early Phase 1
• Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer PatientsStatus unknownNCT04248621Phase 4
• Cardiovascular Events in GnRH Agonist vs. AntagonistStatus unknownNCT04182594Phase 2
• Efficacy and Tolerance of an Ovarian Stimulation Protocol Combining Follicle Stimulating Hormone (FSH) and Degarelix Acetate in Female Candidates for Fertility Preservation Before Chemotherapy for Breast CancerCompletedNCT03947151Phase 2
• Long Antagonist Protocol for IVF With Single Luteal Dose of DegarelixStatus unknownNCT03240159Phase 3
• Phase IV Study to Evaluate Bone Mineral Density in No-bone Metastatic Prostate Cancer Treated With DegarelixStatus unknownNCT03202381Phase 4
• Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate CancerActive, not recruitingNCT02799706Phase 3
• A Trial to Evaluate Safety of Firmagon® (Degarelix) in Indian Patients Diagnosed With Advanced Hormone-dependent Prostate CancerCompletedNCT02726009Phase 4
• A Trial Evaluating Two Subcutaneous Injection Techniques and Intramuscular Administration of Degarelix in Patients With Prostate CancerCompletedNCT02526784Phase 3
• Endothelial Function in Prostate Cancer Patients on Degarelix vs. Luteinizing Hormone-Releasing Hormone AgonistsCompletedNCT02475057Phase 4
• Pharmacokinetics of Degarelix in Chinese Patients With Prostate CancerCompletedNCT02468284Phase 1
• High-Dose Brachytherapy in Treating Patients With Prostate CancerCompletedNCT02346253Not applicable
• Study of Olaparib (± Degarelix) Given to Men With Intermediate/High Risk Prostate Cancer Before ProstatectomyCompletedNCT02324998Phase 1
• A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomyWithdrawnNCT02159690Phase 2
• An Extension Long-term Safety and Tolerability Trial of Degarelix in Chinese Patients With Prostate CancerCompletedNCT02015871Phase 3
• Comparison of HT Concomitant With RT vs RT Alone in Patients With a Detectable PSA After ProstatectomyActive, not recruitingNCT01994239Phase 2
• A Study to Compare the Effect of ASP3550 With Goserelin in Patients With Prostate CancerCompletedNCT01964170Phase 3
• Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell TransplantationActive, not recruitingNCT01746849Phase 2
• One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese PopulationCompletedNCT01744366Phase 3
• Degarelix in the Treatment of Endometriosis RecurrenceCompletedNCT01712763Phase 3
• Use of Degarelix in Controlled Ovarian Hyperstimulation (COH) Protocol for Women With PoliCystic Ovarian Syndrome (PCOS)CompletedNCT01709942Phase 3
• Degarelix Neo-Adjuvant Radical Prostatectomy TrialCompletedNCT01674270Phase 2
• Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive Castrate Resistant Prostate Cancer (CRPC)WithdrawnNCT01630967Phase 2
• A Phase II Study of Degarelix in the Management of Non-Metastatic Hormone-Refractory Prostate CancerTerminatedNCT01545882Phase 2
• Firmagon (Degarelix) Intermittent TherapyTerminatedNCT01512472Phase 4
• Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate CancerCompletedNCT01491971Phase 2
• Feasibility and Toxicity of Degarelix for Prostate Downsizing Prior to Permanent Seed Prostate BrachytherapyCompletedNCT01446991Phase 2
• Initiation of Androgen Deprivation Therapy for Prostate Cancer Using Degarelix Followed by LeuprolideCompletedNCT01344564Not applicable
• Study to Find Maintenance Dose for Periodic Administration of ASP3550CompletedNCT01261572Phase 2
• Open-Label, Randomised Parallel-Group StudyWithdrawnNCT00728533Phase 3
• Phase II Study of ASP3550 in Patients With Prostate CancerCompletedNCT00568516Phase 2

← Degarelix overview